


(I)



(I)

or a stereoisomeric form of the compound of formula I, or a physiologically tolerated salt of the compound of formula I; and



a third component comprising a pharmaceutically tolerated excipient;

wherein the first component has a concentration from about 2 to about 20 mg and the second component has a concentration from about 0.3% to about 50% of the first component.

20. A method of treating an immunological disease comprising administering to a patient in need of such treatment, a therapeutically effective amount of a solid composition comprising

a first component comprising 5-methyl-4'-trifluoromethyl-4-isoxazolecarboxanilide;

a second component comprising a compound of formula I



or a stereoisomeric form of the compound of formula I, or a physiologically tolerated salt of the compound of formula I; and



a third component comprising a pharmaceutically tolerated excipient;

wherein the first component has a concentration from about 2 to about 20 mg and the second component has a concentration from about 0.3% to about 50% of the first component.

26. A method of treating a disease comprising administering to a patient in need of such treatment, a therapeutically effective amount of a solid composition comprising

a first component comprising 5-methyl-4'-trifluoromethyl-4-isoxazolecarboxanilide;

a second component comprising a compound of formula I



or a stereoisomeric form of the compound of formula I, or a physiologically tolerated salt of the compound of formula I; and

B3

a third component comprising a pharmaceutically tolerated excipient;

wherein the first component has a concentration from about 2 to about 20 mg and the second component has a concentration from about 0.3% to about 50% of the first component, and wherein the disease is atopic dermatitis, asthma, urticaria, rhinitis, uveitis, type II diabetes, cystic fibrosis, colitis, or hepatic fibrosis.

27. A method of treating a cancerous disease comprising administering to a therapeutically effective amount of a solid composition comprising

a first component comprising 5-methyl-4'-trifluoromethyl-4-isoxazolecarboxanilide;

a second component comprising a compound of formula I